Influence of Childhood Maltreatment, Adulthood Stressful Life Events, and Affective Temperaments on Premenstrual Mental Symptoms of Nonclinical Adult Volunteers.
TEMPS-A
affective temperament
childhood maltreatment
neglect
premenstrual mental symptoms
structural equation modeling
Journal
Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
09
2019
accepted:
10
12
2019
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
epublish
Résumé
Previous studies have shown that childhood maltreatment is associated with premenstrual dysphoric disorder (PMDD). In this study we analyzed how multiple factors, such as childhood maltreatment, affective temperaments, and adult life events influence the severity of premenstrual mental (PMM) symptoms in nonclinical adult volunteers from the community. A total of 204 participants were recruited and administered the following self-administered questionnaire surveys: PMDD scale, visual analogue scale, Patient Health Questionnaire-9, Life Experience Survey, Temperament Evaluation of Memphis, Pisa, Paris, and San Diego autoquestionnaire version, and the Child Abuse and Trauma scale. In addition to single and multiple regression analyses, structural equation modeling was used for the statistical analyses. A history of neglect indirectly predicted PMM symptoms through affective temperaments in nonclinical adult volunteers. Three affective temperaments (irritable, cyclothymic, and anxious) directly predicted PMM symptoms. This study is the first to report that childhood maltreatment, particularly neglect, indirectly predicted PMM symptoms through affective temperaments. The results of our study suggest that affective temperament is a mediator of the influence of childhood maltreatment on PMM symptoms.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have shown that childhood maltreatment is associated with premenstrual dysphoric disorder (PMDD). In this study we analyzed how multiple factors, such as childhood maltreatment, affective temperaments, and adult life events influence the severity of premenstrual mental (PMM) symptoms in nonclinical adult volunteers from the community.
METHODS
METHODS
A total of 204 participants were recruited and administered the following self-administered questionnaire surveys: PMDD scale, visual analogue scale, Patient Health Questionnaire-9, Life Experience Survey, Temperament Evaluation of Memphis, Pisa, Paris, and San Diego autoquestionnaire version, and the Child Abuse and Trauma scale. In addition to single and multiple regression analyses, structural equation modeling was used for the statistical analyses.
RESULTS
RESULTS
A history of neglect indirectly predicted PMM symptoms through affective temperaments in nonclinical adult volunteers. Three affective temperaments (irritable, cyclothymic, and anxious) directly predicted PMM symptoms.
CONCLUSION
CONCLUSIONS
This study is the first to report that childhood maltreatment, particularly neglect, indirectly predicted PMM symptoms through affective temperaments. The results of our study suggest that affective temperament is a mediator of the influence of childhood maltreatment on PMM symptoms.
Identifiants
pubmed: 32021194
doi: 10.2147/NDT.S232925
pii: 232925
pmc: PMC6954089
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-10Informations de copyright
© 2020 Wakatsuki et al.
Déclaration de conflit d'intérêts
TI has received personal fees from Mochida Pharmaceutical, Takeda Pharmaceutical, Eli Lilly, Janssen Pharmaceutical, MSD, Taisho Toyama Pharmaceutical, Yoshitomiyakuhin, and Daiichi Sankyo; grants from Shionogi, Astellas, Tsumura, and Eisai; and grants and personal fees from Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Kyowa Pharmaceutical Industry, Pfizer, Novartis Pharma, and Meiji Seika Pharma; and is a member of the advisory boards of Pfizer, Novartis Pharma, and Mitsubishi Tanabe Pharma. NH has received personal fees from Janssen Pharmaceutical, Yoshitomiyakuhin, Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, Novartis Pharma, and Meiji Seika Pharma. YF has received honoraria from Otsuka Pharmaceutical and grants from Otsuka Pharmaceutical, Novartis Pharma, and Shionogi. JM has received personal compensation from Otsuka Pharmaceutical, Eli Lilly, Astellas, and Meiji Yasuda Mental Health Foundation and grants from Pfizer. MI has received personal compensation from Otsuka Pharmaceutical, Pfizer, Eli Lilly, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Meiji Seika Pharma, Janssen Pharmaceutical, Takeda Pharmaceutical, MSD, Dainippon Sumitomo Pharma, and Eisai; grants from Otsuka Pharmaceutical, Eli Lilly, Eisai, Shionogi, Takeda Pharmaceutical, MSD, and Pfizer; and is a member of the advisory board of Meiji Seika Pharma. IK has received honoraria from Astellas, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Janssen Pharmaceutical, Kyowa Hakko Kirin, Lundbeck, Meiji Seika Pharma, MSD, Mylan, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Shionogi, Shire, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, Tanabe Mitsubishi Pharma, Tsumura, and Yoshitomiyakuhin, and has received research/grant support from Astellas, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Kyowa Hakko Kirin, Mochida Pharmaceutical, MSD, Novartis Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, and Takeda Pharmaceutical, and is a member of the advisory board of Dainippon Sumitomo Pharma. The authors report no other conflicts of interest associated with this work.
Références
Neuropsychiatr Dis Treat. 2017 Oct 05;13:2559-2568
pubmed: 29042786
J Affect Disord. 2013 Sep 5;150(2):216-22
pubmed: 23684516
J Affect Disord. 2005 Mar;85(1-2):85-92
pubmed: 15780679
Neuropsychiatr Dis Treat. 2016 Apr 12;12:823-32
pubmed: 27110116
Am J Psychiatry. 1995 Jun;152(6):833-42
pubmed: 7755111
Child Abuse Negl. 1995 Mar;19(3):315-23
pubmed: 9278731
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):500-5
pubmed: 20138198
Am J Psychiatry. 2012 Feb;169(2):141-51
pubmed: 22420036
Psychol Rep. 2007 Dec;101(3 Pt 1):952-60
pubmed: 18232454
J Psychiatr Res. 2018 Apr;99:129-141
pubmed: 29454220
Lancet. 2001 Sep 15;358(9285):881-7
pubmed: 11567704
Arch Womens Ment Health. 2003 Aug;6(3):203-9
pubmed: 12920618
JAMA. 1999 Nov 10;282(18):1737-44
pubmed: 10568646
Womens Health Issues. 2010 Jan-Feb;20(1):58-65
pubmed: 20123176
Arch Womens Ment Health. 2011 Oct;14(5):383-93
pubmed: 21786081
J Affect Disord. 2015 Nov 15;187:203-10
pubmed: 26342173
Biol Psychiatry. 2015 Feb 15;77(4):335-44
pubmed: 25127741
Child Abuse Negl. 1998 Sep;22(9):915-29
pubmed: 9777261
Am J Psychiatry. 1999 Jun;156(6):837-41
pubmed: 10360120
Patient. 2010 Jun 1;3(2):125-32
pubmed: 22273361
Psychosom Med. 2003 Sep-Oct;65(5):849-56
pubmed: 14508031
Health Psychol. 2007 Mar;26(2):201-13
pubmed: 17385972
Psychol Med. 1993 Aug;23(3):679-90
pubmed: 8234575
J Affect Disord. 2005 Mar;85(1-2):3-16
pubmed: 15780671
J R Soc Med. 2012 Apr;105(4):151-6
pubmed: 22532655
J Clin Psychiatry. 2004 Oct;65(10):1314-22
pubmed: 15491233
Compr Psychiatry. 2016 Nov;71:33-38
pubmed: 27607359
Psychiatry Res. 2016 Feb 28;236:142-147
pubmed: 26708440
J Affect Disord. 2016 Jan 15;190:47-55
pubmed: 26480211
Prim Care Companion CNS Disord. 2014 Jul 24;16(4):null
pubmed: 25664213
J Psychiatr Pract. 2008 Jan;14(1):13-21
pubmed: 18212599
J Consult Clin Psychol. 1978 Oct;46(5):932-46
pubmed: 701572
World Psychiatry. 2010 Jun;9(2):103-10
pubmed: 20671899
J Affect Disord. 2014 Apr;158:101-7
pubmed: 24655773
Neuropsychiatr Dis Treat. 2015 Aug 14;11:2079-90
pubmed: 26316754
J Womens Health (Larchmt). 2014 Sep;23(9):729-39
pubmed: 25098348
PLoS One. 2014 May 15;9(5):e97421
pubmed: 24831231
Eur Rev Med Pharmacol Sci. 2013;17(15):2065-79
pubmed: 23884828